SCHEMBL693150

SCHEMBL693150

COc1ccc2c(O)cc(C(=O)O)nc2c1Cl

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.50
IGFBP3 P17936 2/20 0.48
ALOX15 P16050 1/20 0.47
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PDE4D Q08499 3/20 0.43
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KMO O15229 1/20 0.40
PIM1 P11309 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
HTT P42858 1/20 0.39
IGFBP5 P24593 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10082469 0.89 PDE4D (0.40) GPR35IGFBP3ALOX15KDM4EL3MBTL1
SCHEMBL561469 0.88 PDE4D (0.45) PDE4DMAPTTDP1PIM1PDE4A
SCHEMBL1166903 0.88 PDE4D (0.45) GPR35IGFBP3PDE4DPIM1PDE4A
SCHEMBL1166603 0.85 KDM4A (0.43) GPR35IGFBP3PDE4DALDH1A1PDE4A
SCHEMBL1166810 0.83 GPR35 (0.50) GPR35IGFBP3ALOX15KDM4EL3MBTL1
SCHEMBL10082467 0.82 PDE4D (0.40) IGFBP3PDE4DALDH1A1MAPTRAB9A
SCHEMBL15257129 0.81 KDM4E (0.50) GPR35IGFBP3KDM4EMAPTRAB9A
SCHEMBL13079806 0.81 CYP19A1 (0.39) ALOX15PDE4DALDH1A1MAPTRAB9A
SCHEMBL975858 0.80 ALOX15 (0.56) GPR35IGFBP3ALOX15KDM4EL3MBTL1
SCHEMBL27863966 0.78 ABCB11 (0.39) KDM4EPDE4DMAPTTDP1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2709613-B2 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2020-08-12 EP disclosed
EP-2709613-B2 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2020-08-12 EP disclosed
US-10456414-B2 Methods for treating HCV GILEAD PHARMASSET LLC (US) 2019-10-29 US disclosed
US-10456414-B2 Methods for treating HCV GILEAD PHARMASSET LLC (US) 2019-10-29 US disclosed
EP-2709613-B1 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2017-11-29 EP disclosed
EP-2709613-B1 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC (US) 2017-11-29 EP disclosed
US-20170189439-A1 METHODS FOR TREATING HCV GILEAD SCIENCES, INC. 2017-07-06 US disclosed
US-20170189439-A1 METHODS FOR TREATING HCV GILEAD SCIENCES, INC. 2017-07-06 US disclosed
US-20170042961-A1 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC 2017-02-16 US disclosed
US-20170042961-A1 METHODS FOR TREATING HCV GILEAD PHARMASSET LLC 2017-02-16 US disclosed
US-20090227491-A1 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-09-10 US disclosed
US-20090227491-A1 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-09-10 US disclosed
US-20090227491-A1 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-09-10 US disclosed
CN-101489564-A Antiviral phosphinate compounds GILEAD SCIENCES INC (US) 2009-07-22 CN disclosed
EP-2043658-A2 ANTIVIRAL PHOSPHINATE COMPOUNDS Gilead Sciences, Inc. (US) 2009-04-08 EP disclosed
WO-2008005565-A9 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES INC (US) 2009-01-29 WO disclosed
US-20080057031-A1 Antiviral phosphinate compounds GILEAD SCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080057031-A1 Antiviral phosphinate compounds GILEAD SCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080057031-A1 Antiviral phosphinate compounds GILEAD SCIENCES, INC. (US) 2008-03-06 US disclosed
WO-2008005565-A2 ANTIVIRAL PHOSPHINATE COMPOUNDS GILEAD SCIENCES, INC. (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080057031-A1 Antiviral phosphinate compounds PHOSPHO1, MAVS, ITPA GPR35 4082/4885IGFBP3 1910/4885ALOX15 3442/4885
US-20090227491-A1 ANTIVIRAL PHOSPHINATE COMPOUNDS PHOSPHO1, MAVS, ITPA GPR35 4082/4885IGFBP3 1910/4885ALOX15 3442/4885
US-10456414-B2 Methods for treating HCV HAVCR2, HCCS, LIPC GPR35 2316/4885IGFBP3 1312/4885ALOX15 658/4885
US-20170189439-A1 METHODS FOR TREATING HCV HAVCR2, HCCS, LIPC GPR35 2316/4885IGFBP3 1312/4885ALOX15 658/4885
US-20170042961-A1 METHODS FOR TREATING HCV HAVCR2, HCCS, LIPC GPR35 2316/4885IGFBP3 1312/4885ALOX15 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.